Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan K-T, Alpermann T, Kuo M-C, Rostami S, Matthews J, Sanada M, Liu L-Z, Shiraishi Y, Miyano S, Chendamarai E, Hou H-A, Malnassy G, Ma T, Garg M, Ding L-W, Sun Q-Y, Chien W, Ikezoe T, Lill M, Biondi A, Larson R A, Powell B L, Lübbert M, Chng W J, Tien H-F, Heuser M, Ganser A, Koren-Michowitz M, Kornblau S M, Kantarjian H M, Nowak D, Hofmann W-K, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih L-Y, Mathews V, Koeffler H P
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Leukemia. 2016 Aug;30(8):1672-81. doi: 10.1038/leu.2016.69. Epub 2016 Apr 11.
Acute promyelocytic leukemia (APL) is a subtype of myeloid leukemia characterized by differentiation block at the promyelocyte stage. Besides the presence of chromosomal rearrangement t(15;17), leading to the formation of PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) fusion, other genetic alterations have also been implicated in APL. Here, we performed comprehensive mutational analysis of primary and relapse APL to identify somatic alterations, which cooperate with PML-RARA in the pathogenesis of APL. We explored the mutational landscape using whole-exome (n=12) and subsequent targeted sequencing of 398 genes in 153 primary and 69 relapse APL. Both primary and relapse APL harbored an average of eight non-silent somatic mutations per exome. We observed recurrent alterations of FLT3, WT1, NRAS and KRAS in the newly diagnosed APL, whereas mutations in other genes commonly mutated in myeloid leukemia were rarely detected. The molecular signature of APL relapse was characterized by emergence of frequent mutations in PML and RARA genes. Our sequencing data also demonstrates incidence of loss-of-function mutations in previously unidentified genes, ARID1B and ARID1A, both of which encode for key components of the SWI/SNF complex. We show that knockdown of ARID1B in APL cell line, NB4, results in large-scale activation of gene expression and reduced in vitro differentiation potential.
急性早幼粒细胞白血病(APL)是髓系白血病的一种亚型,其特征为早幼粒细胞阶段的分化阻滞。除了存在导致PML-RARA(早幼粒细胞白血病-维甲酸受体α)融合形成的染色体重排t(15;17)外,其他基因改变也与APL有关。在此,我们对初发和复发的APL进行了全面的突变分析,以鉴定与PML-RARA在APL发病机制中协同作用的体细胞改变。我们使用全外显子测序(n = 12)以及随后对153例初发和69例复发APL中的398个基因进行靶向测序,探索了突变图谱。初发和复发的APL每个外显子平均含有8个非同义体细胞突变。我们在新诊断的APL中观察到FLT3、WT1、NRAS和KRAS的反复改变,而在髓系白血病中常见突变的其他基因中很少检测到突变。APL复发的分子特征表现为PML和RARA基因频繁出现突变。我们的测序数据还证明了先前未鉴定的基因ARID1B和ARID1A中功能丧失突变的发生率,这两个基因均编码SWI/SNF复合物的关键成分。我们表明,在APL细胞系NB4中敲低ARID1B会导致基因表达的大规模激活,并降低体外分化潜能。